Merck & Co., Inc. MRK
At closeNov 3, 2026, 6:17 PM EST
After hours · Nov 3, 6:17 PM ET
- YTD
- +37.44%
- 1 year
- +75.38%
- Market cap
- 356.93B
- Revenue (ttm)
- 67.38B
- Profit margin
- 3.64%
- EPS (ttm)
- 0.99
- Shares out
- 2.47B
- P/E ratio
- 146.13
- Forward P/E
- 16.03
- Dividend
- 3.40 (2.29%)
- Ex-dividend date
- Sep 14, 2026
- YTD return
- +37.44%
- 1-year return
- +75.38%
- Volume
- 8.86M
- Avg volume
- 10.33M
- Open
- 147.02
- Previous close
- 148.36
- Day's range
- 143.47 – 147.62
- 52-week range
- 82.01 – 156.92
- Beta
- 0.12
- Analysts
- Buy
- Price target
- 160.29 (+10.8%)
- Earnings date
- Feb 2, 2027
2Y +42.80 (+42.01%)
Key statistics
- Enterprise value
- 412.85B
- PEG ratio
- 2.80
- Price / sales
- 5.30
- Price / book
- 8.52
- Dividend yield
- 2.29%
- Payout ratio
- 266.67%
- Revenue growth
- 4.70%
- Free cash flow
- 0
- Total cash
- 7.14B
- Total debt
- 53.91B
- Return on equity
- 0.00%
- Short % of float
- 1.09%
- 50-day average
- 146.78
- 200-day average
- 126.89
Analyst view
Consensus: buy
- Target (low)
- 105.00
- Target (mean)
- 160.29
- Target (high)
- 186.00
- Strong buy5
- Buy14
- Hold9
- Sell0
- Strong sell0
Next earnings
Feb 2, 2027
Expected Feb 2, 2027. Consensus EPS estimate 1.77.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 2, 2027 | Dec 30, 2026 | 1.79 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 2.09 | 2.49 | +0.40 | +19.14% |
| Aug 4, 2026 | Jun 30, 2026 | -0.27049 | -0.13 | +0.14 | +51.94% |
| Apr 30, 2026 | Mar 31, 2026 | -1.47 | -1.28 | +0.19 | +12.93% |
| Feb 3, 2026 | Dec 31, 2025 | 2.01 | 2.04 | +0.03 | +1.49% |
| Oct 30, 2025 | Sep 30, 2025 | 2.36 | 2.58 | +0.22 | +9.32% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | Freedom Broker | main | Hold | Hold |
| Nov 2, 2026 | Cantor Fitzgerald | main | Neutral | Neutral |
| Oct 30, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 30, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Oct 30, 2026 | Guggenheim | main | Buy | Buy |
| Oct 26, 2026 | Barclays | main | Overweight | Overweight |
About Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Website
- merck.com
News
Merck gets US FDA emergency use nod for treatment of screwworm in dogs
3 Stocks That Did Well the Last Time the Fed Raised Rates Aggressively
Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial
Merck's Pipeline Could Be Its Next Big Growth Driver. Its Latest Earnings Offer a Clue.
Buy, Sell, or Hold? Tuesday’s Top Upgrades and Downgrades: AON, Bloom Energy, Chevron, Cloudflare, Marvell Technologies, Lumentum Holdings, Merck & Co., Roku, X-Energy, and More Merck Initiates Its ENHANCE-3 Phase 3 Randomized Clinical Trial Evaluating OHTUVAYRE For The Prevention Of Chronic Obstructive Pulmonary Disease
Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations
Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugs Cantor Fitzgerald Maintains Neutral on Merck & Co, Raises Price Target to $155
Merck To Present New Data Across Its HIV Treatment And Prevention Pipeline And Portfolio At HIV Drug Therapy Glasgow 2026
Your note
Sign in to keep a note on MRK — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHATTOPADHYAY SANAT | Officer | Conversion of Exercise of derivative security | Apr 28, 2026 | 200,675 |
| DAVIS ROBERT M | Chief Executive Officer | Conversion of Exercise of derivative security | Apr 28, 2026 | 450,351 |
| DELUCA RICHARD ROBERT JR. | Officer | Sale | Aug 11, 2026 | 110,167 |
| GUINDO CHIRFI | Officer | Sale | Aug 12, 2026 | 36,613 |
| LI DEAN Y | Officer | Conversion of Exercise of derivative security | Apr 28, 2026 | 94,431 |
| LITCHFIELD CAROLINE | Chief Financial Officer | Conversion of Exercise of derivative security | Apr 28, 2026 | 92,300 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.20% | 226,999,837 | 32.84B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.54% | 161,323,174 | 23.34B | Jun 29, 2026 |
| State Street Corporation | 4.88% | 120,413,256 | 17.42B | Jun 29, 2026 |
| Wellington Management Group, LLP | 3.50% | 86,249,283 | 12.48B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 2.75% | 67,738,969 | 9.80B | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.46% | 60,744,214 | 8.79B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.18% | 78,411,374 | 11.34B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.59% | 63,996,884 | 9.26B | Jun 29, 2026 |
| SCHWAB STRATEGIC TRUST-Schwab US Dividend Equity ETF | 1.47% | 36,188,606 | 5.24B | Aug 30, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 32,874,367 | 4.76B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 32,060,543 | 4.64B | Aug 30, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.24% | 30,514,312 | 4.41B | Sep 29, 2026 |
